Bill > S627

This bill, titled the Medical Innovation Prize Fund Act, aims to incentivize the development of new medicines and improve access to them by establishing a "Fund for Medical Innovation Prizes" and eliminating exclusive marketing rights for drugs and biological products. Instead of relying on patents and market exclusivity, which the bill argues are inefficient and unfair, it proposes to award "prize payments" to entities that develop medically important innovations. A Board of Trustees, composed of government officials and representatives from various sectors including health insurance providers, medical research, and consumer interests, will oversee the awarding of these prizes based on criteria such as the number of patients who would benefit, the therapeutic advantage over existing treatments, and the addressing of priority health needs like infectious diseases and rare conditions. The bill also dedicates a portion of the fund to "Open Source Dividend prizes" to encourage the sharing of knowledge and technology, and establishes a new annual fee on health insurance providers to help fund the prize program.